Eric Coldwell
Stock Analyst at Baird
(3.77)
# 735
Out of 4,981 analysts
188
Total ratings
60%
Success rate
5.26%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Outperform | $9 → $14 | $10.10 | +38.61% | 9 | Sep 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $175.01 | +27.99% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $182.91 | +6.06% | 11 | Aug 25, 2025 | |
| PINC Premier | Maintains: Neutral | $22 → $27 | $26.63 | +1.41% | 9 | Aug 20, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $152.24 | +33.34% | 13 | Aug 13, 2025 | |
| OMI Owens & Minor | Maintains: Outperform | $10 → $7 | $5.34 | +31.09% | 19 | Aug 12, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $290 → $302 | $277.95 | +8.65% | 14 | Jul 25, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $490.64 | -0.13% | 19 | Jul 23, 2025 | |
| IQV IQVIA Holdings | Maintains: Neutral | $159 → $196 | $187.22 | +4.69% | 18 | Jul 23, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $118 → $140 | $152.89 | -8.43% | 14 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $9.29 | +72.23% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $531 → $688 | $711.42 | -3.29% | 17 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $61.65 | -27.01% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $74.98 | -11.98% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.57 | +2,839.30% | 4 | Nov 10, 2017 |
Fortrea Holdings
Sep 3, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $10.10
Upside: +38.61%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $175.01
Upside: +27.99%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $182.91
Upside: +6.06%
Premier
Aug 20, 2025
Maintains: Neutral
Price Target: $22 → $27
Current: $26.63
Upside: +1.41%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $152.24
Upside: +33.34%
Owens & Minor
Aug 12, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $5.34
Upside: +31.09%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $290 → $302
Current: $277.95
Upside: +8.65%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $490.64
Upside: -0.13%
IQVIA Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $159 → $196
Current: $187.22
Upside: +4.69%
Charles River Laboratories International
May 8, 2025
Maintains: Neutral
Price Target: $118 → $140
Current: $152.89
Upside: -8.43%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $9.29
Upside: +72.23%
Nov 7, 2024
Upgrades: Outperform
Price Target: $531 → $688
Current: $711.42
Upside: -3.29%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $61.65
Upside: -27.01%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $74.98
Upside: -11.98%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.57
Upside: +2,839.30%